RESEARCH AND DEVELOPMENT
- HOME
- Research and Development
- Message from Research Scientists
Message from Research Scientists
Patient-friendly and enables accurate treatment
In recent years, drug discovery using new modalities (new materials) such as mRNA, siRNA, antisense, and peptides have become popular; however, these compounds are rapidly decomposed in vivo and have low mucosal absorption; therefore, novel pharmaceutical formulations are required. For example, long-term sustained release injection using biodegradable polymers may be useful. This formulation can also be applied to conventional small-molecule drugs and enables administration by daily injections to be replaced by a gentle and more accurate injection once every 1 to 3 months. As a result, the patients’ compliance (treatment adherence) is improved. We established a system that can quickly implement a bridge between the formulation design and GMP production suitable for various drugs.
Director :
Hiroaki Okada, Ph.D.
Director of Okada DDS Research Institute Co., Ltd. / Professor Emeritus of Tokyo University of Pharmacy developed "Leuprorelin ®" while being enrolled at Takeda Pharmaceutical Company Limited
Transforming the Trajectory of Our Challenges into the Power for Our Next Leap Forward
We have tackled the nanoparticle and microparticle formulation of over 100 compounds to date. Naturally, not all of these endeavors reached their intended outcomes. Yet even the results of failure were never fruitless; our journey has advanced step by step, spiraling upward toward greater heights.
The unique technologies cultivated in our drug discovery business enable the stable mass production of nanoparticles. Starting with applications in food (supplements), we have expanded into diverse fields including livestock feed, veterinary medicines and supplements, cosmetics, and pesticides. These are not merely applications of technology; they are challenges to deliver new value to society.
The spiral trajectory of our accumulated challenges, forged through overcoming difficulties, possesses a spring-like resilience. Harnessing this resilience as the force for our next leap forward, we continue to strive toward contributing to society and creating new value.
The unique technologies cultivated in our drug discovery business enable the stable mass production of nanoparticles. Starting with applications in food (supplements), we have expanded into diverse fields including livestock feed, veterinary medicines and supplements, cosmetics, and pesticides. These are not merely applications of technology; they are challenges to deliver new value to society.
The spiral trajectory of our accumulated challenges, forged through overcoming difficulties, possesses a spring-like resilience. Harnessing this resilience as the force for our next leap forward, we continue to strive toward contributing to society and creating new value.
Director :Research Institute / Ph.D. in Systems Life Sciences
Noriaki Sagata